Engineered immune cells take aim at childhood leukemia
NCT ID NCT05010564
First seen Nov 16, 2025 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This Phase 1 trial is testing a new type of immunotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not gone away. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack leukemia cells carrying three markers: CD19, CD20, and CD22. After a short course of chemotherapy, the modified T cells are infused back into the patient. The main goal is to find a safe dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRICAR-ALL T cells (genetically modified T cells targeting CD19, CD20, and CD22) plus lymphodepletion chemotherapy (fludarabine and cyclophosphamide)
What this could lead to
If successful, this could offer a new treatment option for children and young adults with B-cell acute lymphoblastic leukemia that has returned or not responded to standard therapy.
What could go wrong
This is an early Phase 1 trial with only 38 participants, so it is primarily testing safety and dosing. The treatment may cause serious side effects like cytokine release syndrome, and it is not yet proven to work or be widely available.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.